new/era/mabs

Executive Summary

new/era/mabs is a privately held German biotechnology company based in Munich, founded in 2018. The company has developed a scalable antibody discovery and manufacturing platform that leverages murine, human, and camelid sources to deliver results four times faster than conventional methods. Their technology enables rapid, tailored, and infinite screening options for precise diagnostics and therapeutics, with applications in oncology, immunology, and pandemic preparedness. By accelerating the timeline from discovery to production, new/era/mabs aims to become a key partner for research institutions and biopharma companies seeking efficient antibody solutions. Despite its innovative platform, new/era/mabs remains in an early stage with limited public information on funding, valuation, or commercial traction. The company's success hinges on validating its platform through partnerships and advancing its pipeline. With a focus on speed and versatility, new/era/mabs addresses a critical need in the antibody therapeutics market, but faces competition from established players and other platform companies. Its ability to secure strategic collaborations and demonstrate scalability will be crucial for growth.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership for antibody discovery40% success
• Q4 2026Series A funding round closure60% success
• Q1 2027Platform expansion into new therapeutic areas (e.g., neurology)30% success